Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data
Proton-pump inhibitors, PPIs, are widely prescribed and are available over the counter for prolonged reduction of stomach acid production and related disorders. PPIs irreversibly inhibit the hydrogen/potassium ATPase in gastric parietal cells. Recent retrospective studies have described an associati...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Pharmacoepidemiology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2813-0618/2/3/23 |
| _version_ | 1797577899439554560 |
|---|---|
| author | Tigran Makunts Haroutyun Joulfayan Kenneth Ta Ruben Abagyan |
| author_facet | Tigran Makunts Haroutyun Joulfayan Kenneth Ta Ruben Abagyan |
| author_sort | Tigran Makunts |
| collection | DOAJ |
| description | Proton-pump inhibitors, PPIs, are widely prescribed and are available over the counter for prolonged reduction of stomach acid production and related disorders. PPIs irreversibly inhibit the hydrogen/potassium ATPase in gastric parietal cells. Recent retrospective studies have described an association between PPI use and depression. However, there is conflicting evidence that PPI therapy improves depressive symptoms. Considering the widespread use and over-the-counter availability of these drugs, further investigation into depression adverse event was warranted with a larger-scale postmarketing set of reports. Here we analyzed over 125,923 reports from the FDA Adverse Event Reporting System consisting of PPI and histamine-2 receptor antagonist monotherapy records and found a statistically significant association between use of PPIs and depression. Additionally, we analyzed each of the six currently marketed PPIs individually and observed the association with the depression adverse reaction for all of them. |
| first_indexed | 2024-03-10T22:15:35Z |
| format | Article |
| id | doaj.art-a0c3b89a05184c309f3e046af9d2268b |
| institution | Directory Open Access Journal |
| issn | 2813-0618 |
| language | English |
| last_indexed | 2024-03-10T22:15:35Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmacoepidemiology |
| spelling | doaj.art-a0c3b89a05184c309f3e046af9d2268b2023-11-19T12:28:53ZengMDPI AGPharmacoepidemiology2813-06182023-08-012327228210.3390/pharma2030023Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance DataTigran Makunts0Haroutyun Joulfayan1Kenneth Ta2Ruben Abagyan3Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USASkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USASkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USASkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USAProton-pump inhibitors, PPIs, are widely prescribed and are available over the counter for prolonged reduction of stomach acid production and related disorders. PPIs irreversibly inhibit the hydrogen/potassium ATPase in gastric parietal cells. Recent retrospective studies have described an association between PPI use and depression. However, there is conflicting evidence that PPI therapy improves depressive symptoms. Considering the widespread use and over-the-counter availability of these drugs, further investigation into depression adverse event was warranted with a larger-scale postmarketing set of reports. Here we analyzed over 125,923 reports from the FDA Adverse Event Reporting System consisting of PPI and histamine-2 receptor antagonist monotherapy records and found a statistically significant association between use of PPIs and depression. Additionally, we analyzed each of the six currently marketed PPIs individually and observed the association with the depression adverse reaction for all of them.https://www.mdpi.com/2813-0618/2/3/23proton-pump inhibitorsPPIsFAERSdepressiondrug safetyadverse events |
| spellingShingle | Tigran Makunts Haroutyun Joulfayan Kenneth Ta Ruben Abagyan Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data Pharmacoepidemiology proton-pump inhibitors PPIs FAERS depression drug safety adverse events |
| title | Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data |
| title_full | Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data |
| title_fullStr | Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data |
| title_full_unstemmed | Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data |
| title_short | Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data |
| title_sort | depression events associated with proton pump inhibitors in postmarketing drug surveillance data |
| topic | proton-pump inhibitors PPIs FAERS depression drug safety adverse events |
| url | https://www.mdpi.com/2813-0618/2/3/23 |
| work_keys_str_mv | AT tigranmakunts depressioneventsassociatedwithprotonpumpinhibitorsinpostmarketingdrugsurveillancedata AT haroutyunjoulfayan depressioneventsassociatedwithprotonpumpinhibitorsinpostmarketingdrugsurveillancedata AT kennethta depressioneventsassociatedwithprotonpumpinhibitorsinpostmarketingdrugsurveillancedata AT rubenabagyan depressioneventsassociatedwithprotonpumpinhibitorsinpostmarketingdrugsurveillancedata |